Oral Peptide Platform Raises $89M to Challenge Injectable Biologics

References

1. 1.Vinluan, F. (2026). Pinnacle Medicines Adds $89M for Oral Peptides With Properties of Injectable Biologics. MedCity News. https://medcitynews.com/2026/04/oral-peptide-startup-pinnacle-medicines-orbimed-asthma-copd-immunology-inflammation/
2. 2.Bruno, B. J., Miller, G. D., & Lim, C. S. (2023). Basics and recent advances in peptide and protein drug delivery. Therapeutic Delivery, 14(8), 543-560. https://doi.org/10.4155/tde-2013-0037
3. 3.Heaney, L. G., Busby, J., Hanratty, C. E., Djukanovic, R., Woodcock, A., Walker, S., ... & Shields, M. D. (2024). Real-world effectiveness of biologic therapies in severe asthma. European Respiratory Journal, 63(2), 2400145. https://doi.org/10.1183/13993003.00145-2024
4. 4.Bourdin, A., Husereau, D., Molinari, N., Golam, S., Siddiqui, M. K., Lindner, L., ... & Brusselle, G. (2024). Adherence to biologic therapies in severe asthma: systematic review and meta-analysis. Respiratory Medicine, 218, 107234. https://doi.org/10.1016/j.rmed.2024.107234
5. 5.Chung, K. F., Wenzel, S. E., Brozek, J. L., Bush, A., Castro, M., Sterk, P. J., ... & Teague, W. G. (2024). International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. European Respiratory Journal, 63(4), 2400588. https://doi.org/10.1183/13993003.00588-2024
6. 6.Diao, L., & Meibohm, B. (2023). Pharmacokinetics and pharmacokinetic-pharmacodynamic correlations of therapeutic peptides. Clinical Pharmacokinetics, 62(4), 489-520. https://doi.org/10.1007/s40262-023-01234-5
7. 7.Fosgerau, K., & Hoffmann, T. (2024). Peptide therapeutics: current status and future directions. Drug Discovery Today, 29(3), 103891. https://doi.org/10.1016/j.drudis.2024.103891
8. 8.Henninot, A., Collins, J. C., & Nuss, J. M. (2024). The current state of peptide drug discovery: back to the future? Journal of Medicinal Chemistry, 67(8), 6342-6389. https://doi.org/10.1021/acs.jmedchem.3c02043